CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS Charlotte Lab successfully implemented WNV NAT testing on the Panther Testing Platform on Monday...
This is the first update to the original CTS communication distributed on July 6th. As previously co...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
We have now added a new section called the "Assay History List" to the "At A Gla...
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...